Gazette.govt.nzPursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
| Product: | Rinvoq |
| Active Ingredient: | Upadacitinib hemihydrate 15.4mg equivalent to upadacitinib 15mg |
| Dosage Form: | Modified release tablet |
| New Zealand Sponsor: | AbbVie Limited |
| Manufacturer: | AbbVie Ireland NL B.V., Sligo, Ireland |
| Product: | Rinvoq |
| Active Ingredient: | Upadacitinib hemihydrate 30.7mg equivalent to upadacitinib 30mg |
| Dosage Form: | Modified release tablet |
| New Zealand Sponsor: | AbbVie Limited |
| Manufacturer: | AbbVie Ireland NL B.V., Sligo, Ireland |
| Product: | Rinvoq |
| Active Ingredient: | Upadacitinib hemihydrate 46.1mg equivalent to upadacitinib 45mg |
| Dosage Form: | Modified release tablet |
| New Zealand Sponsor: | AbbVie Limited |
| Manufacturer: | AbbVie Ireland NL B.V., Sligo, Ireland |
Dated this 3rd day of August 2023.
DEREK FITZGERALD, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).